Almac Sciences has made three appointments to its team. Denis Geffroy has been promoted to vice president (VP) business development, with global responsibility. Geffroy joined Almac in 2004 and most recently served as senior business manager, Europe.
He has previously held technical and commercial roles at Chiroscience/ChiroTech and ICI/Synetix Chiral Technologies.
Almac has also appointed Charles Shields as VP peptides operations. Shields was previously US-based VP global business development for Avecia’s oligonucleotides business and has also held other roles at the company.
Helen McKeever has also joined the Almac as preclinical programme manager. McKeever is a biochemist with more than 20 years experience at contract research organisations (CRO), most recently as senior project manager at Covance.
India-based CRO Alticure Research has appointed C Kannan Janakiraman as president and CEO. Janakiraman was previously CEO of Huclin Research.
Encorium has appointed Sari Laitinen to its board of directors to replace Jyrki Mattilawho has resigned from the post. Laitinen is the founder and owner of a US legal services firm and previously served as director, US capital markets at Ernst & Young Oy.
Baljit Chadha has joined the board of directors at Warnex, a provider of laboratory services to the pharma and biotech sectors. Chadha is president of Balcorp, an international trade and marketing firm, and has “significant expertise” in the sector.
TranScrip Partners has appointed David Oxlade as chairman of the board. Oxlade has previously worked as CEO of Xenova, chairman of BioAnaLab, president of Syva and also spent 14 years at Boehringer Mannheim before it was acquired by Roche.